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Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are not only 
among the most commonly used therapeutic agents worldwide 
but also the most commonly prescribed medications for pain 
relief  and arthritis management globally. Despite of  tremendous 
total usage, the side effects correlated with gastrointestinal, 
hepatic or renal damages and occasional cardiovascular risk 
leaded to the confinement of  NSAIDs - related concomitant 
therapies [1, 2]. NSAIDs exert anti-inflammatory effects mainly 
through reduction of  prostaglandin biosynthesis by inhibiting 
the activity of  cyclooxygenase (COX) activity, which exists in two 
predominant isoforms, COX-1 and COX-2 [3-5]. Specifically, 
COX-1 is constitutively expressed in most tissues to maintain 
routine functions of  organs. COX-2 shows basal expression by 
tissue-specific distribution and is activated to correspond with 
inflammatory stimulation [6, 7]. However, recent evidence has 
revealed that selective inhibition of  COX-2 activity-inducing 
inflammatory events reduce the potential side effects caused by 
traditional NSAIDs [8, 9].
Celecoxib (Celebrex®) was the first of  the COX-2 selective 
inhibitors (coxibs) approved by Food and Drug Administration 
(FDA) in 1998 for the following indications: arthritis, acute pain, 
and familial adenomatous polyposis (FAP) [10, 11]. Although 
celecoxib has very poor water solubility, orally administered 
celecoxib shows good absorption and promising gastrointestinal 
safety. Under fasting condition, the rate and extent of  absorption 
of  celecoxib are dose-proportional. Celecoxib is primarily 
metabolized by cytochrome P4502C9 (CYP2C9) in the liver and 
cytochrome P4503A4 (CYP3A4) is involved to a small extent. 
After hepatic metabolism, three metabolites without COX-2 
inhibitory activity are derived from celecoxib, and subsequently, 
some of  the parental compound is excreted in urine and feces. 
Additionally, Tmax was delayed by ~1 h and AUC increased by 10-
20% when celecoxib was administered with a high-fat diet [12].
Based on a recent study, celecoxib accounted for 0.2% to 21.2% 
of  total NSAID sales around the world [13], suggesting a 
great demand for the drug in the global market. In light of  the 
Abstract
The bioequivalence study to compare a new formulation of  celecoxib to its reference formulation was designed as an 
open-label, randomized, single-dose, two-way crossover, comparative bioavailability study by using a validated LC/MS/MS 
method. In order to determine the plasma concentrations of  celecoxib, a sensitive LC/MS/MS method was developed. 
The method was validated to possess adequate specificity, linearity, precision, accuracy and stability. The linearity of  cali-
bration curve was assessed between the concentration intervals (5–2000 ng/mL) with a correlation coefficient over 0.999. 
Regarding pharmacokinetic investigation, the mean celecoxib AUC0-t values from the test and reference drug formulations 
were 7360.44 ± 1714.14 h•ng/mL and 7267.48 ± 2077.68 h•ng/mL, respectively, and the corresponding AUC0-∞ values 
were 8197.45 ± 2040.31 h•ng/mL and 7905.54 ± 2286.12 h•ng/mL, respectively. The Cmax of  the test and reference drugs 
was 705.30 ± 290.63 ng/mL and 703.86 ± 329.91 ng/mL, respectively, and the corresponding Tmax was 3.4 ± 1.6 h and 2.9 
± 1.4 h. Lastly, the T1/2 values of  the test and reference drugs were 13.9 ± 7.9 h and 12.9 ± 7.7 h, respectively. The 90% 
confidence intervals for AUC0-t, AUC0-∞, and Cmax were 97.00-108.85, 98.01-112.09, and 93.20-116.13, respectively, satisfy-
ing the bioequivalence criteria of  80-125% range. In conclusion, these results demonstrated that the bioequivalence of  two 
formulations of  celecoxib was established successfully by utilizing present developed LC/MS/MS method.
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guidance for bioavailability/bioequivalence studies stipulated 
by Taiwan Food and Drug Administration (TFDA), assessment 
of  bioequivalence to establish therapeutic equivalence via a 
comparative bioavailability evaluation based on pharmacokinetics 
of  a test (generic) and a reference drug formulation is regarded as 
the required criterion for marketing approval of  generic medicinal 
products [14]. Certainly, the clinical safety and tolerability of  the 
generic formulation also need to be evaluated.
The purpose of  this study was to investigate the bioequivalence 
of  generic celecoxib (200 mg capsule) in comparison with the 
reference formulation Celebrex® capsule 200 mg in healthy 
volunteers by using a validated LC/MS/MS method.
Materials and Methods
Drug information
Capsules containing 200mg celecoxib were obtained from 
manufacturers. Celecoxib 200mg capsule (Synmosa Biopharma 
Co., Ltd.) and Celebrex® 200mg capsule (celecoxib 200mg capsule, 
Pfizer) served as test and reference formulations, respectively.
Chemicals and reagents
HPLC-grade acetonitrile (ACN) was purchased from Mallinckrodt 
(USA). All other chemicals were analytical grade and obtained 
from Merck (Darmstadt, Germany).
Preparation of  plasma samples for LC/MS/MS analysis
Plasma samples were allowed to thaw in a water bath at room 
temperature. 200μl of  plasma from each sample was mixed 
with 50μl of  ACN/H2O containing 0.3ng/μl celecoxib-d4 as an 
internal standard. The mixture was centrifuged at 3000 rpm for 10 
min after addition of  500μl of  100% ACN to each sample. The 
solvent layer was transferred to which 500μl of  H2O was added 
for further analysis.
The plasma concentrations of  celecoxib were determined by a 
validated LC/MS/MS method. Chromatographic separation 
was performed on Agilent ZORBAX XDB-C18, 2.1 × 50 mm 
internal size, 5μm particle size (Agilent Technologies, USA)  with 
a mobile phase consisting of  ACN/H2O/formic acid (60/40/0.2) 
via an optimum flow rate of  0.3ml/min. The LC/MS/MS 
system comprised Waters Alliance 2795 Separations Module and 
Micromass Quattro Ultima with MassLynx V4.0 SP4.
Validation
Procedures of  validation and acceptance criteria were in 
accordance with “FDA Bio-analytical Method validation 
guidelines [15].” Validation was performed by evaluating 
specificity, linearity, precision, accuracy, recovery and stability. 
The precision was defined by the coefficient of  variation (%CV) 
and accuracy was based on the relative error (%RE) [(mean 
calculated concentration–nominal concentration) × 100%/
nominal concentration]. The precision should be ≤ 15.0%, except 
for lower limit of  quantification value (LLOQ), where it should 
be ≤ 20.0%. For accuracy (%RE) acceptance criteria, the % RE 
of  the mean value should be within ± 15.0%, except for LLOQ, 
where it should be within ± 20.0%.
Ethics and subject enrollment
This study was performed in accordance with the Taiwan Law of  
Pharmaceutical Affairs, Good Clinical Practices, Good Laboratory 
Practices, local regulatory requirements, and the principles 
enunciated in the Declaration of  Helsinki. The sample size which 
would expect to achieve the 80-125% confidence interval limit was 
based on the result of  pilot study. Thereby, a total of  38 healthy 
Taiwanese volunteers participated in this study. Signed informed 
consent was obtained from all individual participants enrolled in 
the study. The enrolled subjects were between the ages of  20 and 
36 years and weighed 45.5 to 81.3 kg. All subjects were healthy, as 
determined by complete physical and clinical examinations before 
the study. The subjects were instructed to avoid any medication 
for at least 1 month prior to and during the study.
Study design and clinical protocol
This was an open-label, single-dose, randomized, two-period, two-
sequence, two-treatment, crossover, comparative bioavailability 
study under fasting conditions. This trial was conducted to 
demonstrate therapeutic equivalence through pharmacokinetic 
means, and hence, the bioavailability of  celecoxib from the 
two study drug formulations was compared. To this end, 38 
healthy adult volunteers were screened after obtaining consent 
for enrollment. Subjects who met the eligibility criteria were 
randomly assigned in equal numbers to one of  the two dosing 
sequences, T-R or R-T. For example, subjects randomized to the 
T-R sequence received the test product in Period 1, and then 
received the reference product in Period 2 after a 7-day washout 
period.
During each study period, the subjects were hospitalized at a 
study facility from 9 pm before dosing of  day 1 until 12 h after 
dosing. On Day 1, the subjects’ vital signs were checked. Before 
drug administration, it was confirmed that subjects had fasted by 
evaluating if  their blood sugar levels were in the normal range 
(60-120mg/dL). Thereafter, the test or reference drug was 
administered orally with 240 mL of  water maintained at room 
temperature. Water up to 3 L per day was offered on request. 
Alcohol, coffee, tea, cocoa, or cola were not permitted for 
48 h before each dosing until the last sampling in each period. 
No beverages were allowed 1 h before and until 2 h after drug 
administration. The subjects were required to fast overnight (for 
at least 10 h) before dosing and a minimum of  4 h thereafter. 
Standardized meals were provided on Day 1, including lunch and 
dinner, at 4 and 10 h after dosing, respectively, during each period. 
During housing, meal plans were identical for both periods. 
Information on the standardized meal, and its quantity and time 
of  provision were recorded on the relevant raw data forms. 
During housing, consumption of  tobacco was not allowed.
Blood samples for pharmacokinetic analysis were collected in a 
pre-labeled vacutainer tubes containing sodium heparin in each 
period at pre-dose (0), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 
and 48 h after administration of  each formulation. Approximately 
10mL of  venous blood sample as blank was collected prior to 
drug administration. Approximately 10mL of  venous blood 
samples were obtained according to the above sampling schedule. 
The actual collection time for each blood sample was recorded. 
The blood samples collected at each time point were centrifuged 
at 1900 × g for 10 min at 4°C to separate plasma. Then, the 
separated plasma was stored at - 20°C for further analysis.
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Pharmacokinetic and statistical analysis
Pharmacokinetic and statistical evaluations were performed for 
samples from subjects who completed the study according to the 
protocol. Any value of  plasma concentration below the limit of  
quantification (LOQ) was considered as zero for computation. 
The pharmacokinetic parameters of  celecoxib from the two for-
mulations, such as AUC0-t, AUC0-∞, Cmax, Kel, Tmax, T½ and MRT, 
were determined and calculated using WinNonlin professional 
software version 6.3 (Pharsight Corporation, Mountain View, 
CA). Each parameter was presented as arithmetic mean (Mean) 
with standard deviation (SD).
The pharmacokinetic parameters of  celecoxib from the two 
formulations were statistically evaluated using analysis of  variance 
(ANOVA) appropriate for the experimental design of  this study. 
The statistical model included factors accounting for the following 
sources of  variations: sequence, subjects within a sequence, 
period, and treatment. For AUC and Cmax, the ratio of  geometric 
means for the ln-transformed data was compared. The statistical 
significance of  the ratio was assessed by appropriate analysis 
of  variance (ANOVA) using SAS® version 9.2 (SAS Institute 
Inc., Cary NC). Statistical inferences including 90% confidence 
intervals and Schuirmann’s two one-sided test procedures were 
evaluated. To establish bioequivalence, the 90% confidence 
intervals for the ratio of  the geometric means with respect to the 
test/reference products were to fall within the range of  80-125 % 
according to ln-transformed data.
Results
Method validation
Method validation was conducted in accordance with the currently 
accepted “FDA Bio-analytical Method validation guidelines” 
for industry [15]. In order to confirm the reliability of  our 
method, the accuracy, precision, selectivity, linearity and stability 
were needed to be validated. First, blank plasma samples from 
six independent sources were prepared and analyzed without 
addition of  celecoxib and internal standard (IS, celecoxib-d4). As 
expected, no significant interference peaks were observed in the 
chromatograms (Figure 2A). The results revealed that minimal 
endogenous compounds or chemical reagents would affect the 
retention times of  celecoxib or IS due to the specificity of  signal. 
The representative chromatograms demonstrated the retention 
times of  celecoxib and IS were 1.76 and 1.74 minutes, respectively 
(Figure 2B and C). The linearity was established in terms of  
eight spiked plasma samples at nominal concentrations range 
5-2000ng/ml. The calibration curves were linear at indicated 
concentration range with a correlation coefficient over 0.999 (Y 
= 0.01495 X - 0.00720, r2 = 1.00). Suitable precision (0.8 to 7.6%) 
and accuracy were observed which highlighted the reliability of  
analytical method (Table 1). Additionally, the designated LLOQ (5 
ng/mL) was acceptable to determine the plasma concentration of  
celecoxib in specimens which obtained from endpoint sampling 
as  48 h post-dose according to present study design.
With respect to the precision and accuracy corresponding to 
intra-day and inter-day conditions, the intra-day and inter-day 
precisions were 2.5-3.1% and 1.7-5.5%, respectively. Meanwhile, 
the intra-day and inter-day accuracies were 97.4-106.6% and 99.5-
102.7%, respectively (Table 2). To evaluate the extraction recov-
ery, the celecoxib chromatograms obtained from plasma and solu-
tion were used to determine the ratio based on their mean peak 
areas. The mean extraction recovery of  celecoxib was 87.9% in 
response to three spiked celecoxib concentrations (15, 100 and 
1500ng/mL). Moreover, plasma samples containing celecoxib 
for two concentrations (15 and 1500ng/mL) were subject to in-
vestigate the stability. As results summarized in Table 3, the ana-
lyte was found to be stable no matter in short-term, long-term, 
post-processing and repeated freeze–thaw cycles conditions. Our 
results demonstrated that present bioanalytical method were reli-
able in specificity, sensitivity, precision, accuracy and stability over 
studied range for which it was appropriate to be applied for fur-
ther bioequivalence study.
Subject demographics
Among the 45 subjects screened for the study, 38 were randomized 
and completed the study without protocol deviations at Mackay 
Memorial Hospital Tamshui Branch. Eventually, these 38 subjects 
were assessed in the pharmacokinetic analysis and bioequivalence 
evaluation. This subject population included 22 male subjects 
(57.8%) and 16 female subjects (42.2%) (Table 4).
Pharmacokinetic properties
The mean plasma concentration-time curves of  celecoxib 
after single dose oral administration of  the test and reference 
formulations were presented in Figure 3. Celecoxib plasma 
concentration-time curves were similar for both formulations. 
Pharmacokinetic parameters of  the test and reference treatments 
were listed in Table 5. After administration, the time to peak 
concentration (Tmax) of  the test and reference treatments was 3.4 
± 1.6 h and 2.9 ± 1.4 h, respectively. The maximum plasma level 
of  celecoxib of  the test and reference formulations was 705.30 ± 
290.63ng/mL and 703.86 ± 329.91ng/mL. AUC0-t was 7360.44 ± 
1714.14 h•ng/mL and 7267.48 ± 2077.68 h•ng/mL, and AUC0-∞ 
was 8197.45 ± 2040.31 h•ng/mL and 7905.54 ± 2286.12 h•ng/
mL. The terminal elimination half-life (T1/2) was 13.9 ± 7.9 h 
Figure 1. Structure of  celecoxib.
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Figure 2. Representative chromatograms of  celecoxib and celecoxib-d4 (IS) in human plasma specimens. (A) Blank plasma; 
(B) plasma sample spiked with celecoxib at LLOQ (5ng/mL); (C) plasma sample spiked with celecoxib-d4 at 1ng/mL.
Table 1. Precision and accuracy of  celecoxib measurement for linearity.
Nominal conc. (ng/mL) Observed value (ng/mL) (Mean ± SD) (n = 5) Precision (%) Accuracy (%)
5 4.87 ± 0.37 7.6 97.4
10 10.3 ± 0.6 5.8 103
20 19.9 ± 1.0 5 99.5
50 49.7 ± 1.2 2.4 99.4
200 199 ± 4 2 99.5
500 512 ± 12 2.3 102.4
1000 988 ± 18 1.8 98.8
2000 2001 ± 17 0.8 100.1
Table 2. Inter and Intra-day precision and accuracy of  celecoxib in human plasma.
Nominal value (ng/mL) Intra-day (ng/mL) (n = 6) Inter-day (ng/mL) (n = 5)
Mean ± SD Prec. (%) Acc. (%) Mean ± SD Prec. Acc. 
5 5.33 ± 0.15 2.8 106.6 5.10 ± 0.28 5.5 102
15 15.7 ± 0.4 2.5 104.7 15.4 ± 0.5 3.2 102.7
100 97.4 ± 2.7 2.8 97.4 99.7 ± 3.2 3.7 99.7
1500 1496 ± 46 3.1 99.7 1493 ± 2.7 1.7 99.5
SD, standard deviation; Prec., Precision; Acc., accuracy
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and 12.9 ± 7.7 h. In addition, a total of  four adverse events were 
reported by three subjects. Neither serious adverse event nor 
obvious abnormality of  vital signs was observed throughout the 
study. Thereby, these results indicated that two formulations were 
well tolerated.
Statistical bioequivalence
In order to evaluate the bioequivalence between the two 
formulations, statistical analysis was performed for AUC0-t, 
AUC0-∞, and Cmax. The results are presented in Table 5. The 90% 
confidence intervals (CI) for the ratios (test versus reference) 
obtained using ln-transformed values of  AUC0-t, AUC0-∞, and Cmax 
were 97.00%–108.85%, 98.01%–112.09%, and 93.20%–116.13%, 
respectively. In summary, the above-mentioned parameters 
showed no significant differences (p > 0.05) between the two 
formulations in the ANOVA assessment, and the 90% CI were 
within the acceptable range of  80–125% for bioequivalence 
evaluation.
Discussion
While avoiding the traditional NSAID-induced adverse effects, 
celecoxib showed clinical efficacy and tolerability equal to those 
Table 3. Stability of  celecoxib in human plasma.
Parameter Celecoxib
Stability Nominal conc. (ng/mL) Mean conc. ± SD (ng/mL) Accuracy (%)
Short-terma 15 14.2 ± 0.6 94.7
1500 1512 ± 43.9 100.8
Long-termb 15 14.6 ± 0.2 99.3
1500 1573 ± 45 103.1
Long-termc 15 15.0 ± 0.8 102
1500 1548 ± 25 101.4
Freeze-thawd 15 14.8 ± 0.2 98.7
1500 1496 ± 63.0 99.7
Freeze-thawe 15 14.6 ± 0.4 97.3
1500 1570 ± 21.1 104.7
Processf 15 14.6 ± 0.4 97.3
1500 1510 ± 75.2 100.7
Processg 15 13.8 ± 1.2 92
1500 1481 ± 80.9 98.7
a At room temperature (25°C) for 26 h, b at -20°C for 36 days, c at -80°C for 36 days, d after four cycle at -20°C, e after four cycle at 
-80°C, f  autosampler at room temperature for 48 h, g sample processing at room temperature.
Table 4. Demographic characteristics.
Characteristic Total (n = 38) Male (n = 22) Female (n = 16)
Age, y 23.3 ± 4.4 24.2 ± 4.9 22.1 ± 3.2
BMI, kg/m2 21.8 ± 2.4 173.0 ± 6.0 159.1 ± 6.1
Weight, kg 61.4 ± 11.0 67.8 ± 8.5 52.6 ± 7.5
Height, cm 167.1 ± 9.1 22.6 ± 2.3 20.7 ± 2.1
*Data were shown as mean ± SD
Figure 3. The mean concentration-time profile of  plasma samples on a semi-logarithmic scale.
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Table 5. A summary of  the pharmacokinetic parameters and confidence interval of  two formulations of  celecoxib 
(reference, R and test, T) after single oral administration in 38 healthy adult volunteers under fasting condition.
Parameter* Test (T) Reference (R) Confidence interval (%)
AUC0-t (hr·ng/mL) 7360.44 ± 1714.14 7267.48 ± 2077.68 97.00-108.85
AUC0-∞ (hr·ng/mL) 8197.45 ± 2040.31 7905.54 ± 2286.12 98.01-112.09
Cmax (ng/mL) 705.30 ± 290.63 703.86 ± 329.91 93.20-116.13
MRT (hr) 18.7 ± 9.4 17.2 ± 10.3 -
Tmax (hr) 3.4 ± 1.6 2.9 ± 1.4 -
T1/2 (hr) 13.9 ± 7.9 12.9 ± 7.7 -
kel (1/hr) 0.07 ± 0.03 0.07 ± 0.03 -
*Data were shown as mean ± SD
of  the first COX-2 selective inhibitors. In contrast, many other 
COX-2 selective inhibitors identified after celecoxib have been 
withdrawn from the U.S. market due to the cardiovascular risks 
associated with long-term usage of  these drugs. Thus, it is impor-
tant to develop an interchangeable generic product of  celecoxib 
in response to medical requirements. In the present study, 38 
healthy volunteers completed the clinical trial for establishment 
of  bioequivalence and evaluation of  safety. We found that the 
mean Cmax of  celecoxib was 705.3 ± 290.6ng/mL and 703.9 ± 
329.9ng/mL in the test and reference products, and these find-
ings were consistent with previous reports that assessed the re-
sults obtained following oral administration of  200mg celecoxib 
[12, 16, 17]. Meanwhile, the Tmax values of  the two formulations 
were comparable to those obtained in earlier studies [18]. Above 
observations demonstrated that those formulations of  celecoxib 
had similar absorption rates after oral administration. However, 
highly variable AUC values ranging from 5157 to 26630 h•ng/mL 
were observed in these findings, which may be related to hepatic 
metabolism differences associated with CYP2C9 polymorphism, 
which is predominantly responsible for celecoxib metabolism [19, 
20]. Intriguingly, we found that Cmax values obtained from young-
er women (age range, 20-32) in the present study showed 20% 
higher than those in men, which was in agreement with the data 
for elder women as stated in the medical label of  celecoxib. This 
increase is believed to be attributed to the lower body weight of  
women. However, the present findings are different from those 
obtained in earlier reports, which indicated a 13% lower Cmax and 
longer half-life in women [21].
Conclusion
A sensitive LC/MS/MS method for quantifying celecoxib in 
human plasma was validated effectively for the purpose of  
bioequivalence assessment of  two celecoxib formulations. The 
results showed that the generic formulation was not only well 
tolerated, but also within the acceptable range of  80%–125% 
for bioequivalence validation. Therefore, on the basis of  the data 
obtained from the present study, the test formulation exhibits 
therapeutic equivalence to the reference formulation. Thus, both 
formulations can be prescribed interchangeably.
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